Setmelanotide

Setmelanotide Acetate

N/A Amino Acids · MW: N/A

Ask AI About This

Amino Acids

N/A

Molecular Weight

N/A

Half-life

Approximately 11-16 hours

Research Score

4.6

Studies

Storage

Store lyophilized at -20°C, reconstituted at 2-8°C

What is Setmelanotide?

Setmelanotide is a melanocortin-4 receptor agonist developed for severe genetic obesity syndromes. It reduces hyperphagia and can produce meaningful body-weight reduction in selected patients.

Key Benefits & Mechanisms

reduced hyperphagia

body-weight reduction

MC4R pathway activation

improved satiety signaling

Research Summary

Setmelanotide has shown clinically meaningful reductions in hunger and weight in POMC, PCSK1, and LEPR-related obesity. It is one of the most important mechanistic peptides for rare-disease obesity research.

Related Peptides

Oxyntomodulin

Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide

Oxyntomodulin is a naturally occurring proglucagon-derived peptide that activates GLP-1 and glucagon pathways. It is a key research tool for appetite suppression and energy balance studies in obesity.

Weight Management

Cotadutide

MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist

Cotadutide is a synthetic oxyntomodulin analogue designed to engage both GLP-1 and glucagon receptors. It was developed to improve weight loss and metabolic markers in obesity and type 2 diabetes research.

Weight Management

Mazdutide

IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist

Mazdutide is a long-acting oxyntomodulin-inspired dual agonist being developed for obesity and metabolic disease. It is designed to drive clinically meaningful weight loss while improving glucose and lipid parameters.

Weight Management

Dulaglutide

Recombinant GLP-1 receptor agonist Fc fusion protein

Dulaglutide is a long-acting GLP-1 receptor agonist used primarily in type 2 diabetes. It consistently produces modest weight loss and is widely studied as a benchmark incretin mimetic.

Weight Management